Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Since methylation analysis has become an important tool in forensic genetics, the reliability and credibility of the method must be ensured. After a successful validation and establishment of several pyrosequencing assays using a PyroMark® Q48 Autoprep instrument (Qiagen, Hilden, Germany), we decided to expand the method further purchasing a second instrument. But after initializing this second instrument side by side with the first, the majority of analyses failed (97 samples of 133 samples (73%)). The number of error messages increased rapidly and the average RFU values decreased. After purchasing two anti-vibration weighing tables for the PyroMark® instruments and repeating the analyses under the same conditions and with identical samples the results improved considerably, 115 samples of 130 samples (88%) showed successful and reproducible results. These findings demonstrate the impact of vibrations and percussions on PyroMark® Q48 Autoprep performance and the reliability of methylation analyses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813862 | PMC |
| http://dx.doi.org/10.1007/s00414-021-02716-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Porcine Monoclonal Antibody Targeting a Conserved GP4 Epitope Protects against In Vivo Infection via the Induction of Broad-Spectrum PRRSV Neutralization.
Adv Sci (Weinh)
September 2025
College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, China.
Porcine reproductive and respiratory syndrome virus (PRRSV) imposes substantial economic losses on global swine production. While modified live vaccines remain the primary prevention tool, their efficacy is compromised by the genetic variability of PRRSV. This study developed a broadly neutralizing monoclonal antibody (mAb) that targets a conserved viral epitope as an alternative therapeutic strategy.
View Article and Find Full Text PDFAnalysis of epigenetic biomarkers for diagnosis and assessment of severity in rheumatoid arthritis: a cross-sectional study.
Arthritis Res Ther
August 2025
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma, BIONAND, Málaga, 29590, Spain.
Background: Rheumatoid arthritis (RA) is an autoimmune disease influenced by genetic, environmental, and epigenetic factors. Epigenetic modifications, particularly DNA methylation, in immune-related genes may impact inflammation and immune responses. This study aims to analyze methylation patterns in RA patients and controls to identify diagnostic and prognostic epigenetic biomarkers.
View Article and Find Full Text PDFA Coarse-Grained MD Model for Disorder-To-Order Transitions in PolyQ Aggregation.
J Chem Theory Comput
August 2025
Zernike Institute for Advanced Materials, University of Groningen, Groningen 9747 AG, The Netherlands.
Polyglutamine (polyQ) aggregation plays a central role in several neurodegenerative diseases, including Huntington's disease. To investigate the underlying mechanisms of polyQ aggregation, we developed a coarse-grained molecular dynamics model calibrated using atomistic simulations and experimental data. To assess the model's predictive power beyond the calibrated parameter set, we systematically varied side chain interaction strength and hydrogen bonding strength to explore a broader range of aggregation pathways.
View Article and Find Full Text PDFPhase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Am J Ophthalmol
July 2025
Genentech, Inc. (F.B., L.M., Y.Z., Y.B.I., R.D., M.M., J.C.H., S.S.G., B.Y., J.R.W., H.W., P.L., H.C.), South San Francisco, California, USA.
Purpose: To investigate the safety, tolerability, and efficacy of intravitreal injection of galegenimab, an anti-HtrA1 FAb, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Design: Phase 2, single-masked, randomized clinical trial.
Methods: Eligible GA patients with BCVA letter scores of ≥ 24 letters and baseline GA lesion size 2.
Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
J Acquir Immune Defic Syndr
June 2025
Family Center for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa.
Background: Dolutegravir dispersible tablets (DTG-DTs) are approved for infants 4 weeks or older and ≥3 kg but their suitability for neonates remains unknown.
Methods: PETITE-DTG is a phase I/II, open-label, single-center, 2-stage trial in South Africa to evaluate the pharmacokinetics (PK) and safety of DTG in term neonates of pregnant individuals receiving DTG-based therapy. In stage 1, neonates on standard antiretroviral prophylaxis received a single dose of 5 mg DTG-DT between ≥14 and <28 days of life (cohort 1A) or <14 days of life (cohort 1B), followed by PK and safety assessments.